Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;154 Suppl 1(Suppl 1):3-31.
doi: 10.1002/ijgo.13763.

A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics)

Liona C Poon  1 , Laura A Magee  2 , Stefan Verlohren  3 , Andrew Shennan  2 , Peter von Dadelszen  2 , Eyal Sheiner  4 , Eran Hadar  5   6 , Gerard Visser  7 , Fabricio Da Silva Costa  8 , Anil Kapur  9 , Fionnuala McAuliffe  10 , Amala Nazareth  11 , Muna Tahlak  12 , Anne B Kihara  13 , Hema Divakar  14 , H David McIntyre  15 , Vincenzo Berghella  16 , Huixia Yang  17 , Roberto Romero  18 , Kypros H Nicolaides  19 , Nir Melamed  20 , Moshe Hod  5   6
Affiliations
Review

A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics)

Liona C Poon et al. Int J Gynaecol Obstet. 2021 Jul.
No abstract available

Keywords: management; mean arterial pressure; monitoring; noncommunicable diseases; placental growth factor; pre-eclampsia; prediction; risk stratification; second trimester; soluble fms-like tyrosine kinase-1; third trimester; timed delivery; uterine artery pulsatility index.

PubMed Disclaimer

Conflict of interest statement

Relating to the submitted work, Liona Poon reports receipt of a Health and Medical Research Fund grant to assess the role of pro‐ and antiangiogenic markers for pre‐eclampsia in the second and third trimester (Project No: 136168059), and a grant from Roche Diagnostics for the Asia PROGNOSIS study. Outside the submitted work, LP reports honoraria for lectures from Roche Diagnostics, Ferring Pharmaceuticals, and GE Healthcare; nonfinancial support of in‐kind contributions for research from Roche Diagnostics, PerkinElmer Inc., Thermo Fisher Scientific, and GE Healthcare, and personal fees for consultancy from Roche Diagnostics and Ferring Pharmaceuticals. Outside the submitted work, Stefan Verlohren reports personal fees from Roche Diagnostics, Thermo Fisher Scientific, and Alexion. Outside the submitted work, Fabricio da Silva Costa reports research support from PerkinElmer Inc., and personal fees from Roche Diagnostics and Thermo Fisher Scientific. Outside the submitted work, Kypros H. Nicolaides reports being Director of the Fetal Medicine Foundation. All other authors report no actual or potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Algorithm for “tight” blood pressure control used in the CHIPS trial.a *If systolic blood pressure is ≥160 mmHg, increase dose of existing medication or start new antihypertensive medication to get systolic blood pressure <160 mmHg, regardless of diastolic blood pressure (dBP). aAdapted figure reprinted with permission from Wiley: Magee LA, Khalil A, von Dadelszen P. Pregnancy hypertension diagnosis and care in COVID‐19 era and beyond. Ultrasound Obstet Gynecol. 2020;56:7–10. © 2020 ISUOG. Permission for original figure reprinted from Pregnancy Hypertens. 2019;18. Magee LA, Rey E, Asztalos E, et al. Management of non‐severe pregnancy hypertension – a summary of the CHIPS Trial (Control of Hypertension in Pregnancy Study) research publications. 156–162. © 2019, with permission from Elsevier.
See this image and copyright information in PMC

References

    1. Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention. Int J Gynecol Obstet. 2019;145 Suppl 1(Suppl 1):1‐33. - PMC - PubMed
    1. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924‐926. - PMC - PubMed
    1. Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens. 2014;4:97‐104. - PubMed
    1. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014;4:105‐145. - PubMed
    1. Lowe SA, Bowyer L, Lust K, et al. SOMANZ guidelines for the management of hypertensive disorders of pregnancy 2014. Aust N Z J Obstet Gynaecol. 2015;55:e1–e29. - PubMed